tbuckley/cabot-search huggingface dataset:
Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series.
Authors: N. Bartlett, L. E. Grove, D. A. Kennedy, E. L. Sievers, A. Forero-Torres
Journal: Journal of Clinical Oncology (2010)

8062 Background: Brentuximab vedotin is an anti-CD30 antibody conjugated to the highly potent antitubulin agent, monomethyl auristatin E (MMAE), by a plasma-stable linker. Brentuximab vedotin selectively induces apoptosis in CD30+ cells by binding, internalizing, and releasing MMAE. In phase I clinical studies, good tolerability and antitumor activity were demonstrated in patients with CD30+ hematologic malignancies. This case series describes patients who have experienced relapse and were retreated with brentuximab vedotin. Methods: Heavily pretreated, relapsed or refractory patients with CD30+ hematologic malignancies have been retreated with brentuximab vedotin in 3 multicenter studies. Patients had SD with decreasing tumor volume or better (Cheson 2007) with prior brentuximab vedotin treatment, and subsequently experienced relapse. In their retreatment experiences, patients received brentuximab vedotin IV infusions of 1 mg/kg qweek or 1.8 mg/kg q3week, depending on the study. Results: Across these 3 studies, 7 patients had 8 retreatment experiences. Patients had either ALCL (1) or HL (6); ages ranged from 28–39 years. At baseline prior to retreatment, ECOG performance statuses were 0/1 (7), or 2 (1). Since the prior experience with brentuximab vedotin, the number of chemotherapy regimens was either 0 (4) or 1–3 (4), and 1 patient had an autologous stem cell transplant. Adverse events that occurred in more than 1 patient with retreatment were upper respiratory tract infection (3) and peripheral sensory neuropathy (2); all treatment-related AEs were G1/2 in severity. Among the retreatment experiences, there were 2 CR, 4 PR, and 2 SD; tumor regression was observed in all instances. All objective responses were observed 5–13 weeks after the start of retreatment, and retreatment response durations of 52+ weeks have been demonstrated. Conclusions: Retreatment with brentuximab vedotin was well tolerated. Objective responses were observed (6 of 8) with brentuximab vedotin retreatment in this heavily pretreated population. Enrollment to a phase 2 retreatment study in patients who previously experienced an objective response to brentuximab vedotin is ongoing. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Seattle Genetics, Inc. Seattle Genetics, Inc. Seattle Genetics, Inc.
Characteristics and Outcome of Therapy-Related MDS Developing after Primary Cancer in Children.
Authors: R. Ammann, M. Zecca, D. Betts, J. Harbott, M. Trebo, H. Hasle, M. van den Heuvel-Eibrink, J. Starý, E. Bergstraesser, C. Peters, J. Vormoor, U. Kontny, B. Strahm, U. Duffner, P. Noellke, F. Locatelli, C. M. Niemeyer
Journal: Blood (2005)
Radiologic Response to Neoadjuvant Treatment Predicts Histologic Response in Thymic Epithelial Tumors
Authors: Geoffrey B. Johnson, Marie Christine Aubry, Eunhee S. Yi, Chi Wan Koo, Sarah M. Jenkins, Yolanda I. Garces, Randolph S. Marks, Stephen D. Cassivi, Anja C. Roden
Journal: Journal of Thoracic Oncology (2016)
Hair Loss Is a Potential Side Effect of Novel Oral Anticoagulants – Findings From the Dresden Noac Registry (NCT01588119)
Authors: Vera Gelbricht, Christina Koehler, Sebastian Werth, Ulrike Haensel, Thomas Schreier, Tittl Luise, Maria Eulitz, Ines Beyer-Westendorf, Jan Beyer-Westendorf
Journal: Blood (2012)
Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN).
Authors: K. J. Harrington, A. Berrier, M. Robinson, E. Remenar, M. Housset, F. Hurtado de Mendoza, N. Compton, M. Lau, P. Legenne, R. Kumar
Journal: Journal of Clinical Oncology (2010)

5505 Background: Lapatinib is an oral, reversible small-molecule inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2). EGFR overexpression is common in SCCHN and is a negative prognostic factor. Methods: Eligible pts had locally advanced unresected stage III/IVA/IVB SCCHN (oral cavity, oropharynx, hypopharynx, larynx) and ECOG performance status (PS) 0-2. Pts received lapatinib 1500 mg or placebo daily, 3 cycles of cisplatin 100 mg/m2 (days 1, 22, 43) and radiotherapy (70 Gy/35 fractions/7 weeks) followed by maintenance lapatinib/placebo. The primary endpoint was complete response rate (CRR) by independent review 6 months post-CRT. Results: 67 pts (33 placebo, 34 lapatinib; median age 56 years) were recruited: 52%, 45%, and 3% had ECOG PS of 0, 1, and 2, respectively; 18% had stage III and 82% stage IV disease. Disease subsites were: oropharynx 64%, hypopharynx 16%, larynx 12%, and oral cavity 7%. Lapatinib combined with CRT was well tolerated; grade 3/4 toxicities during CRT were balanced between treatment arms, with grade 3 rash occurring in 3% and diarrhea in 6% of pts being more frequent with lapatinib. Of the most common adverse events (experienced by >20% of pts) no grade 3/4 toxicities were observed during maintenance therapy except grade 3 localized edema in 3% of lapatinib pts and weight loss in 3% of placebo pts. CRT dose intensities were not adversely affected by lapatinib: median radiation dose 70 Gy (lapatinib and placebo) and duration 49 days (lapatinib) and 50 days (placebo); median cisplatin dose 260 mg/m2 (lapatinib) and 280 mg/m2 (placebo). CRR at 6 months post-CRT was 36% with placebo vs 53% with lapatinib in the intent-to-treat population (all pts randomized to lapatinib or placebo). The early data showed hazard ratios for progression-free and overall survival by independent review of 0.71 (95% CI 0.34-1.52) and 0.70 (95% CI 0.31-1.63), respectively. An updated survival analysis will be presented at the ASCO Annual Meeting. Conclusions: Lapatinib was well tolerated when combined with CRT. There is an early signal of clinical activity based on CRR at 6 months post-CRT. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline
Eleanor Mary Briggs
Authors: Michael Briggs, Paula Briggs
Journal: BMJ (2016)

Eleanor Mary Briggs (nee Clarke) was educated at Hutchesons’ Girls’ Grammar School. She did her house jobs at the Victoria Infirmary and Stobhill Hospital. She was married to Douglas within a year of graduating and became a mother within a further year. Her family occupied the early years after she had qualified and eventually comprised five sons. Initially Eleanor fitted working as a schools’ doctor around bringing …
Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases
Authors: Stephen N. Gomperts, Joseph J. Locascio, Sara J. Makaretz, Aaron Schultz, Christina Caso, Neil Vasdev, Reisa Sperling, John H. Growdon, Bradford C. Dickerson, Keith Johnson
Journal: JAMA Neurology (2016)

The causes of cognitive impairment in dementia with Lewy bodies (DLB) and Parkinson disease (PD) are multifactorial. Tau pathologic changes are commonly observed at autopsy in individuals with DLB and PD dementia, but their contribution to these diseases during life is unknown.
The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl Lysophosphatidylethanolamide Disturbs Pro-Fibrogenic Integrin and TGFB Signaling
Authors: J. Su, H. Gan-Schreier, W. Chamulitrat, W. Stremmel, A. Pathil
Journal: Journal of Hepatology (2016)
Defective Plasma Membrane Targeting of P.I661T-ATP8B1, Associated with Familial Intrahepatic Cholestasis, Can be Rescued in Vitro by CFTR Correctors
Authors: W. van der Woerd, C. Wichers, A. Vestergaard, J.P. Andersen, C. Paulusma, R. Houwen, S. Van De Graaf
Journal: Journal of Hepatology (2016)
Thalidomide (HAL) Maintenance Following High-Dose Melphalan with Autologous Stem Cell Transplant (ASCT) for Myeloma.
Authors: Julie E. Chang, Mark B. Juckett, Brad S. Kahl, Teri L. Mitchell, Ronald E. Gangnon, Natalie S. Callander, Walter L. Longo
Journal: Blood (2006)
Safety and Tolerability of Recurrent Hepatitis C Treatment in Post Liver and Liver/Kidney Transplant Patients Treated with Ledipasvir/Sofosbuvir with and without Ribavirin or Sofosbuvir with Ribavirin: Single Center Experience
Authors: K. Selim, B. Elhazin, W. Long, M. Karmanova, J. Salazar, M. Volk
Journal: Journal of Hepatology (2016)
Reductions in Lifetime Risks of Liver-Related Morbidity and Mortality Associated with Novel Direct-Acting Antiviral Regimens Recommended for Treating Genotype 4 Non-Cirrhotic Hepatitis C Patients in the United States
Authors: S. Saab, H. Parisé, S. Virabhak, A. Wang, S. Marx, S. Johnson
Journal: Journal of Hepatology (2016)
Racial and Ethnic Disparities in Etiology of Liver Disease, Tumor Characteristics, and Long-Term Survival of Patients with Hepatocellular Carcinoma: Results of a Single-Center U.S. Cohort of 1998 Patients
Authors: N. Kim, P. Nguyen, M. Ladenheim, Z. Rosenthal, H. Nguyen, G. Garcia, M. Nguyen
Journal: Journal of Hepatology (2016)
Primary Care Physicians Utilizing the Echo Model Equally Effective as Subspecialists Treating HCV using Direct-Acting Antivirals-Only Regimens: Results of the Echo Model
Authors: F. Georgie, S. Nafisi, A. Kohli, K. Thornton, J. Reynolds, A. Moore, R. Gish, J. Scott, P. Deming, M. Sedillo, C. Qualls, T. Box, P. Cox, J. Mera, A. Miller, N. Sussman, S. Khaderi, R. Manch, S. Arora
Journal: Journal of Hepatology (2016)
Hyperoxia Induces Defective Epo-Induced Signal Transduction and Loss of Expansion Capacity in Fanca- and Fancg-Deficient Erythroid Progenitors.
Authors: Marieke von Lindern, Emile van den Akker, Henri van de Vrugt, Godfrey Grech, Fre Arwert, Bob Lowenberg, Ivo Touw
Journal: Blood (2004)
Portal Vein Thrombosis in Patients with Cirrhosis. Incidence and Factors Associated with Its Development
Authors: F. Turon, A. Baiges, A. Garcia-Criado, I. Nuñez, R. Gilabert, C. Bru, A. Berzigotti, J.C. Reverter, S. Seijo, J. Bosch, V. Hernández-Gea, J.C. Garcia-Pagan
Journal: Journal of Hepatology (2016)
The correlation between the number of lymph nodes identified and treatment outcomes in colorectal cancer patients: Single-institution experience.
Authors: L. H. Byrne, F. Janku, B. R. Bird, J. O' Keeffe, E. O' Murchu, L. O' Callaghan, T. Fitzgerald
Journal: Journal of Clinical Oncology (2010)

e14096 Background: Colorectal cancer is the third leading cause of cancer-related death in the Western world. International guidelines recommend evaluating at least 12 locoregional lymph nodes (LNs) on curative surgery to obtain optimal staging information and satisfactory long-term outcomes. In the United States, adequate number of LN identified is achieved in 37% of cases. This study aimed to evaluate the impact of LN status on survival rates in colorectal cancer patients in a single institution setting. Methods: We analyzed data on all patients undergoing radical surgery for colorectal cancer in the Bon Secours Hospital Cork in Ireland between years 2000 and 2006. Numbers of LN identified and number of LN infiltrated were recorded. The lymph node ratio (LNR) was calculated using following formula: LNR = LN infiltrated/LN identified. Overall survival (OS) was used as a primary endpoint. Multivariate analyses were performed on all patients and on following LNR groups: LNR < 0.05, 0.05-0.19, 0.2-0.39, and 0.4-1.0. Covariates included were age, sex, tumor grade, tumor location, lymphovascular and perineural invasion. Results: In total 265 patients were included in this study. The median age was 66 years (range 34 to 89). One hundred and thirty-three patients (50.2%) had 11 or less LNs examined, and 132 patients (49.8%) had 12 or more LNs examined. Mean OS was 73 months for all patients. Patients in the Dukes C2 category (> 3 LN infiltrated and/or tumour infiltrating adjacent structure) who had 12 or more LNs identified had a better OS compared to those who had 11 or less LNs investigated (hazard ratio 0.677 [95%CI 0.45-1.01]). Patients in all Dukes categoreis who had a lower LNR had a significantly better OS than those with a higher LNR (p < 0.0001). Conclusions: Nearly 50% of patients with colorectal cancer undergoing radical surgery had 12 or more lymph nodes investigated. A higher number of LN identified was associated with better survival in the Dukes C2 category. A higher number of LN infiltrated was associated with shorter survival. No significant financial relationships to disclose.
Evidence of Impressive Real World SVR from the Portuguese Ledipasvir/Sofosbuvir and Sofosbuvir Universal Coverage Program to Eradicate (Eliminate) Hepatitis C
Authors: J. Rodrigues, R. Tato-Marmho, H. Mota-Filipe, A.P. Martins, J.C. Martins, V. Andreozzi, B. Vandewalle, J. Félix, E.C. Alves
Journal: Journal of Hepatology (2016)
Prognostic Factors Associated To Achievement Of Complete Or Partial Response In MDS Patients Treated With Azacitidine Outside Clinical Trials
Authors: Massimo Breccia, Maria Teresa Voso, Luca Maurillo, Pasquale Niscola, Francesco Autore, Maria Antonietta Aloe Spiriti, Francesco Buccisano, Caterina Tatarelli, Andrea Tendas, Susanna Fenu, Roberto Latagliata, Giuliana Alimena
Journal: Blood (2013)
Better way to determine the acute:chronic workload ratio?
Authors: Sean Williams, Stephen West, Matthew J Cross, Keith A Stokes
Journal: British Journal of Sports Medicine (2016)

We read with great interest the recent letter, “Time to bin the term ‘overuse’ injury: is ‘training load error’ a more accurate term?”1 and in particular its associated PostScript correspondence, “Are rolling averages a good way to assess training load for injury prevention?”2 We are currently investigating the association between training loads and injury risk,3 and so we have also been considering the best way to model this relationship. We share Dr Menaspa's concerns regarding the use of rolling averages for the calculation of ‘acute’ and ‘chronic’ loads. Namely, that they fail to account for the decaying nature of fitness and …
Factor V Leiden and Prothrombin G20210A Gene Mutations Should Not Be Routinely Screened among Venous Thromboembolism (VTE) Patients in Singapore - This and Patterns of Other Thrombophilic Conditions among Our VTE Patients.
Authors: Heng Joo Ng, Lai Heng Lee, Te-Chih Liu, Lip Kun Tan, Ponnudurai Kuperan
Journal: Blood (2006)
Correction to “Amyloid Precursor Protein, Presenilins, and α-Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer’s Disease”
Authors: Experimental Therapeutics
Journal: Pharmacological Reviews (2006)

As discussed in the “Notice of Concern” published in this issue, several paragraphs in the above article [Suh Y-H and Checler F (2002) Pharmacol Rev 54: [469][1]-526] were republished from an earlier work [Selkoe DJ (2001) Clearing the brain's amyloid cobwebs. Neuron 32: 177-180] without
Functional Analysis of a Cation Transporter OCT6: A Mediator of the Cellular Influx of Adriamycin.
Authors: Yoko Okitsu, Hideo Harigae, Shinichiro Takahashi, Shori Abe, Mitsunori Okabe, Michiaki Unno, Takaaki Abe, Mitsuo Kaku, Takeshi Sasaki
Journal: Blood (2004)
Consistent Simeprevir Resistance Profile in Hepatitis C Virus Genotype 1-Infected Patients Failing Simeprevir Interferon-Free Compared with Interferon-Containing Regimens
Authors: B. Fevery, L. Vijgen, V. Van Eygen, W. Jessner, C. Corbett, M. Schlag, O. Lenz, S. De Meyer
Journal: Journal of Hepatology (2016)
Efficacy of Sofosbuvir/Ledipasvir in Treating Genotype 1 and 4 Hepatitis C for 8/12 Weeks: Results from a Difficult to Treat Cohort
Authors: O.F. Ahmed, E. Thomson, S. Datta, R. Fox, M. Priest, M. Heydtmann, F. Marra, S.T. Barclay
Journal: Journal of Hepatology (2016)
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
Authors: Chad Tang, James W. Welsh, Patricia de Groot, Erminia Massarelli, Joe Y. Chang, Kenneth R. Hess, Sreyashi Basu, Michael A. Curran, Maria E. Cabanillas, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Daniel Karp, Daniel R. Gomez, Adi Diab, Ritsuko Komaki, John V. Heymach, Padmanee Sharma, Aung Naing, David S. Hong
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Little prospective data are available on clinical outcomes and immune correlates from combination radiation and immunotherapy. We conducted a phase I trial (NCT02239900) testing stereotactic ablative radiotherapy (SABR) with ipilimumab. Experimental Design: SABR was given either concurrently (1 day after the first dose) or sequentially (1 week after the second dose) with ipilimumab (3 mg/kg every 3 weeks for 4 doses) to five treatment groups: concurrent 50 Gy (in 4 fractions) to liver; sequential 50 Gy (in 4 fractions) to liver; concurrent 50 Gy (in 4 fractions) to lung; sequential 50 Gy (in 4 fractions) to lung; and sequential 60 Gy (in 10 fractions) to lung or liver. MTD was determined with a 3 + 3 dose de-escalation design. Immune marker expression was assessed by flow cytometry. Results: Among 35 patients who initiated ipilimumab, 2 experienced dose-limiting toxicity and 12 (34%) grade 3 toxicity. Response outside the radiation field was assessable in 31 patients. Three patients (10%) exhibited partial response and 7 (23%) experienced clinical benefit (defined as partial response or stable disease lasting ≥6 months). Clinical benefit was associated with increases in peripheral CD8+ T cells, CD8+/CD4+ T-cell ratio, and proportion of CD8+ T cells expressing 4-1BB and PD1. Liver (vs. lung) irradiation produced greater T-cell activation, reflected as increases in the proportions of peripheral T cells expressing ICOS, GITR, and 4-1BB. Conclusions: Combining SABR and ipilimumab was safe with signs of efficacy, peripheral T-cell markers may predict clinical benefit, and systemic immune activation was greater after liver irradiation. Clin Cancer Res; 23(6); 1388–96. ©2016 AACR.
The Genomic Landscape Of Lineage Switch Acute Leukemia
Authors: Olaf Heidenreich, Ricky Tirtakusuma, Simon Bomken, Dan Williamson, Sarah E Fordham, Hesta McNeill, Claus Meyer, Rolf Marschalek, Josef Vormoor, Andrew Hall, Julie Irving, Helen J Blair, Dan Swan, Bronia Baker, Peter Carey, Nick Bown, David Bourn, Paul Evans, Roderick Skinner, Simon Bailey, Vikki Rand, James Allan
Journal: Blood (2013)
The “Fibrous Nest”: A Biotope including WNT Signals, Extracellular Matrix Remodeling and Stemness in Hepatocellular Carcinoma
Authors: R. Désert, S. Mebarki, M. Desille, M. Sicard, E. Lavergne, S. Renaud, D. Bergeat, L. Sulpice, C. Perret, B. Turlin, B. Clément, Orlando Musso
Journal: Journal of Hepatology (2016)
New Circulating Metabonomic and Mirnomic Biomarkers to Predict Steatosis, Inflammation and Fibrosis Severity in Non-Alcoholic Fatty Liver Disease
Authors: A. Carretero, M. Lopez-Riera, E. Saez, T. Blazquez, I. Conde, A. Zaragoza, R. Jover, A. Lahoz
Journal: Journal of Hepatology (2016)
Genetc and morphologic features for melanoma classification: implications for clinical trials
Authors: S. M. C. Broekaert, R Roy, I Okamoto, Joost van den Oord, J Bauer, C Garbe, RL Barnhill, KJ Busam, AJ Cochran, MG Cook, DE Elder, SW McCarthy, MC Mihm, D Schadendorf, RA Scolyer, A Spatz, BC Bastian
Journal: Journal of Clinical Oncology (2010)
Transcriptome Sequencing of Tumor vs. Surrounding Non-Malignant Lung Tissue in Non-Small Cell Lung Cancer
Authors: Kobe Reynders, Els Wauters, Johan Vansteenkiste, Herbert Decaluwé, Paul De Leyn, Kristiaan Nackaerts, Stéphanie Peeters, Christophe Dooms, Wim Janssens, Diether Lambrechts, Dirk De Ruysscher
Journal: Journal of Thoracic Oncology (2015)
HBsAg Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2A in Chronic Hepatitis B: Long-Term Results of a Global Randomized Controlled Trial
Authors: S.-H. Ahn, P. Marcellin, X. Ma, F. Caruntu, W.Y. Tak, M. Elkhashab, W.-L. Chuang, F. Tabak, R. Mehta, J. Petersen, A. Corsa, E.B. Martins, L.J. Yee, P. Dinh, G. Mani Subramanian, M. Buti, G. Gaeta, G. Papatheodoridis, R. Flisiak, H.L.Y. Chan
Journal: Journal of Hepatology (2016)
Significance of Mutations in the Region Coding for NS3/4 Protease in Patients Infected with HCV Genotype 1b
Authors: T.W. Lapinski, J. Nikolajuk-Stasiuk, M. Rogalska-Plonska, O. Kowalczuk, J. Kisluk, J. Zurawska, J. Nikliński, R. Flisiak
Journal: Journal of Hepatology (2016)
Phase I study of gene mediated cytotoxic immunotherapy (GMCI) for patients with malignant pleural effusion (MPE).
Authors: Charu Aggarwal, Andrew R Haas, Susan Metzger, Laura K. Aguilar, Estuardo Aguilar-Cordova, Andrea G. Manzanera, Evan W. Alley, Tracey L. Evans, Roger B. Cohen, Joshua Bauml, Corey J. Langer, Steven Albelda, Daniel Sterman
Journal: Journal of Clinical Oncology (2016)

3081 Background: GMCI is a tumor-specific immune-stimulator through local delivery of aglatimagene besadenovec, an adenovirus-based vector expressing the HSV-1 thymidine kinase gene (AdV-tk) followed by administration of an anti-herpetic prodrug. Immunogenic tumor cell death and superantigen-mediated T cell stimulation leads to CD8 T cell dependent protection against tumor challenge in preclinical models. Methods: The primary end-point of this dose escalation trialwas safety of GMCI followed by standard chemotherapy. Eligibility included patients (pts) with MPE with a clinical indication for placement of pleural catheter, age > 18 yrs, ECOG PS 0-1, FEV1 > 40% predicted and adequate end organ function. Intra-pleural (IP) AdV-tk was administered at doses of 1x 1012 vector particles (vp) (Cohort 1); 1x1013 vp (Cohort 2); and 1x1013 vp plus celecoxib (Cohort 3). Three pts were treated per cohort with 10 pts in the expansion phase. Valacyclovir (2 gm PO TID x 14 days) started the day after AdV-tk followed by chemotherapy. Secondary end-points included response rate, progression free survival, overall survival and immune response. Results: From 2013 to 2015, 19 pts were enrolled and completed therapy: median age 68 years (range 42-89), 14 malignant mesothelioma (MM) (9 epithelioid, 3 sarcomatoid, 2 biphasic), 4 non-small cell lung cancer (NSCLC) and 1 breast cancer. All 3 pts in cohort 2 experienced transient cytokine release syndrome (CRS), with fever, nausea and chills (grade 2) plus hypotension in 1 pt. Addition of prophylactic celecoxib in cohort 3 (n = 13) reduced the incidence and severity of CRS (23% grade 1, 23% grade 2). Response according to RECIST was evaluable for 16 pts, one pt with MM had a PR, 12 SD, and 3 PD. Eight pts are alive and in active follow up (5-17 months), 3 pts with NSCLC are on active treatment with PFS 6.8-10.6 months and OS 9.4-11.8 months. Immune studies on pt samples are ongoing, and will be presented at the meeting. Conclusions: GMCI can be safely administered at high-doses IP followed by systemic chemotherapy. CRS symptoms due to immune stimulation after IP AdV-tk can be diminished with celecoxib prophylaxis. Phase II studies are warranted to further determine efficacy. Clinical trial information: NCT01997190.
Approved drugs are to be studied for use in Alzheimer’s disease
Authors: Janice Hopkins Tanne
Journal: BMJ (2016)

Many drugs that have been approved by the Food and Drug Administration could be repurposed or used off label to treat Alzheimer’s disease, according to reports from the Alzheimer’s Drug Discovery Foundation conference in New Jersey.

The foundation is supporting 18 approved drugs in repurposing trials. This brings the total number of approved drugs that were being studied for use in treating Alzheimer’s disease in repurposing trials to at least 127, the foundation said.

The drugs discussed at a press briefing on 13 September were tadalafil (Cialis), approved to treat erectile dysfunction, and levetiracetam (Keppra), approved to …
Effects of Healthy- and Acute Liver Failure Plasma on Differentiated Human Heparg Progenitor Cells in Monolayers and Bioartificial Livers
Authors: M. Van Wenum, R. Chamuleau, A. Jongejan, P. Treskes, S. Meisner, E. Hendriks, T. van Gulik, P. Moerland, R. Hoekstra
Journal: Journal of Hepatology (2016)